Carbonyl reductase mutant and application thereof in preparation of levonorgestrel intermediate
By developing high-activity and stability carbonyl reductase mutants, using enzyme catalytic reactions, the problem of low catalytic activity of carbonyl reductase in the prior art was solved, and the efficient synthesis and high stereoscopic selection of levonorgestrel intermediates were achieved. improves industrial production efficiency.
Patent Information
- Application Number
- CN202411139296.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-29
AI Technical Summary
In the prior art, carbonyl reductase has low catalytic activity on ethyl condensate, resulting in insufficient synthesis efficiency and stereoselectivity of levonorgestrel intermediate ethyl hydroxylate, which makes it difficult to meet the needs of industrial production.
Develop highly active and stable carbonyl reductase mutants, and use E. coli strains to carry out enzyme-catalyzed reactions to prepare levonorgestrel intermediates to improve catalytic activity and thermal stability.
The efficient and highly stereoselective synthesis of levonorgestrel intermediates was achieved, the industrial application efficiency of enzyme catalytic preparation was improved, and the production of levonorgestrel drugs was promoted.
Smart Images

Figure BDA0005001976930000031 
Figure BDA0005001976930000051 
Figure BDA0005001976930000061
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of enzyme modification, in particular to a carbonyl reductase mutant and an application thereof in preparing a levonorgestrel intermediate. Background Art
[0002] Levonorgestrel, chemical name: D(-)-17α-ethynyl-17β-hydroxy-18-methylestr-4-en-3-one, is a synthetic steroid drug. It is mainly used as an emergency contraceptive in clinical practice. It can also be used to treat irregular menstruation, functional uterine bleeding and endometriosis.
[0003] Ethyl hydroxylate (chemical name: (2R,3S)-2-ethyl-3-hydroxy-2-(2-((cis)-6-methoxy-3,4-dihydronaphthol-1(2H)ethyl)-1-cyclopentanone, CAS number: 51773-49-0) is a key intermediate of levonorgestrel, which is obtained by asymmetric reduction of dicarbonyl intermediate ethyl condensate (chemical name: (cis)-2-ethyl-2-(2-(6-methoxy-3,4-dihydronaphthol-1(2H)ethyl)-1,3-cyclopentanedione, CAS number: 62298-52-6).
[0004] There are two synthesis methods: cell catalysis and enzyme catalysis. The conversion of ethyl condensation products can be achieved using Saccharomyces cerevisiae cells, but it is not conducive to industrial production due to the long culture time of the strain, low expression of carbonyl reductase, harsh reaction conditions and poor product stereoselectivity. Enzyme catalysis uses carbonyl reductase to catalyze the reaction, which has a short reaction time, mild reaction conditions and good product stereoselectivity, but the carbonyl reductase found so far has low catalytic activity for ethyl condensation products.
[0005] Therefore, there is an urgent need in the art to develop a highly active and stable carbonyl reductase to achieve a highly stereoselective synthesis of the levonorgestrel intermediate ethyl hydroxylate, which is of great significance for the production of levonorgestrel drugs. Summary of the invention
[0006] The invention provides a carbonyl reductase mutant and an application thereof in preparing a levonorgestrel intermediate. The carbonyl reductase mutant is applied to preparing a levonorgestrel intermediate to improve production efficiency and promote industrial application of preparing a levonorgestrel intermediate by enzyme catalysis.
[0007] In view of this, the scheme of the present invention is:
[0008] In a first aspect of the present invention, a carbonyl reductase mutant having an amino acid sequence as shown in SEQ ID NO: 6, 11, 13 or 14 is provided.
[0009] The second aspect of the present invention provides a gene encoding the carbonyl reducing mutant described in the first aspect.
[0010] The third aspect of the present invention provides an expression vector, which contains the gene described in the second aspect.
[0011] The fourth aspect of the present invention provides a strain comprising the expression vector described in the third aspect.
[0012] Furthermore, the strain is Escherichia coli.
[0013] The fifth aspect of the present invention provides a method for producing a carbonyl reductase mutant, comprising the steps of: culturing the strain described in the fourth aspect, and collecting the culture to obtain the carbonyl reductase mutant.
[0014] The sixth aspect of the present invention provides the use of the carbonyl reductase mutant described in the first aspect in catalyzing carbonyl reduction reactions.
[0015] Furthermore, the catalytic carbonyl reduction reaction uses the ethyl condensate as a substrate, and a reduction reaction is performed to prepare an ethyl hydroxylated levonorgestrel intermediate.
[0016] The seventh aspect of the present invention provides a method for preparing a levonorgestrel intermediate, comprising the steps of: adding an ethyl condensate, glucose, glucose dehydrogenase, a reducing coenzyme, a cosolvent, and the carbonyl reductase mutant described in the first aspect or the carbonyl reductase mutant obtained by the production method described in the fifth aspect to a buffer solution, and reacting to obtain an ethyl hydroxylated levonorgestrel intermediate. The specific reaction process is as follows:
[0017]
[0018] Furthermore, the carbonyl reductase mutant is a carbonyl reductase mutant having an amino acid sequence as shown in SEQ ID NO:14.
[0019] Further, the concentration of the ethyl condensate is 10-100 g / L; for example, 10 g / L, 20 g / L, 30 g / L, 40 g / L, 50 g / L, 60 g / L, 70 g / L, 80 g / L, 90 g / L, 100 g / L, preferably 50 g / L.
[0020] Furthermore, the mass ratio of the carbonyl reductase to the ethyl condensate is 1:(100-1000), preferably 1:500.
[0021] Furthermore, the mass ratio of the glucose to the ethyl condensate is 1:(1-2); preferably 1:1.5.
[0022] Furthermore, the mass ratio of the glucose dehydrogenase to the ethyl condensate is 1:(10-1000); preferably 1:100.
[0023] Furthermore, the reducing coenzyme is preferably reduced coenzyme II, and the mass ratio of the reducing coenzyme to the ethyl condensate is 1:(10-1000), and the preferred model is FMII-GD, and the preferred mass ratio is 1:100.
[0024] Furthermore, the buffer solution is a PBS buffer solution with a pH value of 6.0-8.0, preferably a pH value of 7.0.
[0025] Furthermore, the reaction temperature is 20-40°C, the reaction time is 18-24h; preferably, the reaction is carried out at 30°C for 20h; the pH value of the reaction system is 6.0-8.0, preferably the pH value is 7.0.
[0026] Furthermore, the cosolvent includes one or more of DMSO, Tween 60, Tween 80 and Triton X-100; the ratio of the volume of the cosolvent to the total volume of the reaction system is 1:(10-100), preferably 1:20.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] The carbonyl reductase mutant of the invention has high catalytic activity and strong thermal stability, and can be applied to the enzymatic preparation of levonorgestrel intermediates to improve production efficiency, thereby promoting the industrial application of the enzymatic preparation of levonorgestrel intermediates. DETAILED DESCRIPTION
[0029] The technical solution of the present invention will be clearly and completely described below in conjunction with the preferred embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0030] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0031] In the following examples, the term "AnB" used means that the amino acid A at position n is mutated into amino acid B, for example, Q40W means that the amino acid Q at position 40 is mutated into W, and so on.
[0032] Example 1 Synthesis of carbonyl reductase CpADH gene
[0033] The provided carbonyl reductase CpADH amino acid sequence is derived from Caballeronia ptereochthonis, and the amino acid sequence is shown in SEQ ID NO: 1. The CpADH gene is biosynthesized by Wuhan Qingke Biotechnology Co., Ltd. according to the codon preference of Escherichia coli, and the nucleotide sequence is shown in SEQ ID NO: 2.
[0034] SEQ ID NO: 1
[0035] MNRLENKTAIITGGSSGIGLATAQRFVDEGAYVFIVGRRQSELDKAVQQIGRNVTAVQADVTKLDDLDRLFALVKERRGKIDALFANSGSIEHRTLDEITPEHYDATFDVNVRGLIFTVQKALP LMVEGSSIILTSSIAGIKGLHAHGTYSAAKAAVRSLARTWTVEFKGRGIRVNAISPGAIDTPIIDSQVSSAAEADELRAKYAAATPLGRIGRPEEIASAVLFLASDDSSFVAGTDLFVDGGIAQV
[0036] SEQ ID NO: 2
[0037] ATGAACCGCCTGGAAAACAAAACCGCGATTATTACCGGCGGCAGCAGCGGCATTGGCCTGGCGACCGCGCAGCGCTTTGTGGATGAAGGCGCGTATGTGTTTATTGTGGGCCGCCGCCAGAGCGAACTGGATAAAGCGGTGCAGCAGATTGGCCGCAACGTGACCGCGGTGCAGGCGGATGTGACCA AACTGGATGATCTGGATCGCCTGTTTGCCGCTGGTGAAAGAACGCCGCGGCAAAATTGATGCGCTGTTTGCGAACAGCGGCAGCATTGAACATCGCACCCTGGATGAAATTACCCCGGAACATTATGATGCGACCTTTGATGTGAACGTGCGCGGCCTGATTTTTACCGTGCAGAAAGCGCTGCCGCTG ATGGTGGAAGGCAGCAGCATTATTCTGACCAGCAGCATTGCGGGCATTAAAGGCCTGCATGCGCATGGCACCTATAGCGCGGCGAAAGCGGCGGTGCGCAGCCTGGCGCGCACCTGGACCGTGGAATTTAAAGGCCGCGGCATTCGCGTGAACGCGATTAGCCCGGGCCGATTGATACCCCGATTA TTGATAGCCAGGTGAGCAGCGGCGGAAGCGGATGAACTGCGCGCGAAATATGCGGCGGCGACCCCGCTGGGCCGCATTGGCCGCCCGGAAGAAATTGCGAGCGCGGTGCTGTTTCTGGCGAGCGATGATAGCAGCTTTGTGGCGGGCACCGATCTGTTTGTGGATGGCGGCATTGCGCAGGTGTAA
[0038] Example 2 Construction of carbonyl reductase gene CpADH mutant
[0039] Based on CpADH, the binding free energy of virtual saturation mutations of residues at the substrate binding pocket site was calculated by stability prediction software, and key sites that may affect the structure and function of CpADH were found and modified. The amino acid sequence and nucleotide sequence of the modified carbonyl reductase mutant CpADH_1-12 are shown in Table 1. The upstream and downstream primers designed for the above carbonyl reductase mutants are shown in Table 2.
[0040] Table 1: Carbonyl reductase mutant sequences
[0041]
[0042]
[0043]
[0044] Table 2: Mutant sites and primers
[0045]
[0046]
[0047] The carbonyl reductase mutants CpADH_1, CpADH_2, CpADH_3, CpADH_4, CpADH_5, CpADH_6, CpADH_7, CpADH_8 and CpADH_9 used plasmid pET26b-CpADH as template, while the carbonyl reductase combination mutant CpADH_10 used the PCR product of CpADH_8 as template, and the combination mutants CpADH_11 and CpADH_12 both used the PCR product of CpADH_9 as template, and PCR amplification reactions were performed using the upstream and downstream primers in Table 2, respectively.
[0048] The PCR amplification system was: 12.5 μL premixed DNA polymerase, 0.5 μL template, 0.5 μL upstream and downstream primers, and ultrapure water was added to 25 μL. The PCR amplification program was: 98°C pre-denaturation for 3 min; 95°C denaturation for 20 s, 56°C annealing for 20 s, 72°C extension for 10 s, repeated 30 cycles; 72°C final extension for 5 min. After the PCR reaction was completed, 5 μL of PCR product was taken and detected by 1% agarose gel electrophoresis. The results showed that the PCR amplification product band was single and the size was consistent with the theoretical sequence size. The remaining product was recovered and purified, and treated with DpnⅠ to remove the template DNA.
[0049] The constructed CpADH mutant was transformed into Escherichia coli BL21 (DE3) competent cells and spread on LB solid selection medium (formula: 0.5% yeast extract, 1% tryptone, 1% sodium chloride, 1.5% agar) containing 50 μg / mL kanamycin sulfate resistance.
[0050] Transformants were picked on LB solid selective culture plates and cultured in LB liquid medium (formula: 0.5% yeast extract, 1% tryptone, 1% sodium chloride) at 32°C for 16 h. The bacterial liquid was subjected to PCR identification and sequencing verification. Strains with correct sequencing results were stored in glycerol cryovials for subsequent heterologous expression.
[0051] Example 3 Carbonyl reductase gene CpADH and its mutants in Escherichia coli BL21 (DE3)
[0052] Heterologous expression in
[0053] The synthesized expression plasmid pET26b-CpADH containing the carbonyl reductase gene CpADH was transformed into Escherichia coli BL21 (DE3) competent cells and spread on LB solid selection medium containing kanamycin sulfate resistance at a concentration of 50 μg / mL.
[0054] The transformant BL21(DE3)-pET26b-CpADH was picked up on the LB solid selection medium plate, and the seed solution was prepared in 5mL LB liquid medium (37°C, 220rpm, 16h), and then transferred to 50mL LB liquid medium with an inoculum of 1%. The culture was shaken at 37°C and 220rpm until the bacterial solution OD600 = 0.6-0.8, and IPTG with a final concentration of 0.5mM was added, and induced at 18°C for 16h. The bacterial solution after shaking flask culture was centrifuged at 10000rpm for 5min at 4°C, the supernatant was discarded, and the bacteria were collected. The bacteria were washed and resuspended with 0.1MPBS (pH7.0) buffer, and then ultrasonically broken to obtain a clear and transparent whole cell lysate. The supernatant obtained by centrifugation at 12000rpm at 4°C was the crude enzyme solution of carbonyl reductase. The crude enzyme solution of carbonyl reductase CpADH mutant was obtained in the same way.
[0055] Example 4 Establishment of enzyme activity method and standard curve
[0056] The 200 μL reaction system consisted of the following components: 135 μL ddH2O, 40 μL ethyl condensate solution (0.6 mg / mL, dissolved in DMSO), 10 μL NADPH (8 mM) and 15 μL diluted carbonyl reductase enzyme solution.
[0057] Under 30°C, the change of absorbance at 340nm within 2 minutes was measured, and the standard curve was calculated using Excel: y=Kx+b, where y is the absorbance value A340, x is the time (min), and the slope K of the absorbance change within 2 minutes was calculated to further calculate the enzyme activity of carbonyl reductase. The enzyme activity calculation formula is as follows:
[0058] Where K is the slope of the absorbance change, A is the slope of the standard curve, N is the dilution factor of the enzyme solution, V0 is the reaction volume (200 μL in this method), V1 is the volume of the enzyme solution (15 μL in this method), and C is the protein concentration corresponding to the enzyme solution. The protein concentration was determined by the Coomassie Brilliant Blue method.
[0059] The method for preparing the standard curve is as follows: dilute the 2mM NADPH stock solution with 0.1M pH 7.0 PBS to the final concentrations of 0.1mM, 0.2mM, 0.5mM, 0.8mM, and 1mM, respectively measure the absorbance at 340nm (mark the zero point with deionized water), and use Excel to make a standard curve y=Ax+b, where y is the absorbance value A340, x is the NADPH concentration (mM), and A is the slope of the standard curve.
[0060] Example 5 Determination of Enzyme Activity of Carbonyl Reductase Gene CpADH and Its Mutants
[0061] Based on the methods of Examples 1 to 3, CpADH and its mutants were synthesized, constructed and expressed, and crude enzyme solutions of CpADH, CpADH_1, CpADH_2, CpADH_3, CpADH_4, CpADH_5, CpADH_6, CpADH_7, CpADH_8, CpADH_9, CpADH_10, CpADH_11 and CpADH_12 were obtained.
[0062] Activity detection was performed based on the enzymatic activity detection method of carbonyl reductase in Example 4, and the results are shown in Table 3. As can be seen from Table 3, there are 9 mutants with higher enzymatic activity than the wild type, including CpADH_1 (124%), CpADH_2 (111%), CpADH_3 (107%), CpADH_4 (148%), CpADH_6 (125%), CpADH_8 (146%), CpADH_9 (161%), CpADH_11 (194%) and CpADH_12 (203%), among which the relative enzymatic activity of mutant CpADH_12 is the highest, which is 2.03 times that of wild type CpADH.
[0063] Table 3 Initial enzyme activity results of CpADH mutants
[0064]
[0065]
[0066] Example 6 Determination of the thermal stability of carbonyl reductase gene CpADH and its mutants
[0067] Based on the methods of Examples 1 to 3, CpADH and its mutants were synthesized, constructed and expressed to obtain crude enzyme solutions of CpADH, CpADH_1, CpADH_2, CpADH_3, CpADH_4, CpADH_5, CpADH_6, CpADH_7, CpADH_8, CpADH_9, CpADH_10, CpADH_11 and CpADH_12, and the crude enzyme solutions were placed at 30°C and incubated for 12 hours. The enzyme activity was detected according to the detection method of the carbonyl reductase activity in Example 4, and the degree of enzyme activity reduction was calculated. The results are shown in Table 4. The thermal stability of the carbonyl reductase enzyme in the table is reflected by the degree of enzyme activity reduction (the difference in enzyme activity before and after incubation), and the calculation formula is as follows:
[0068] U0 is the initial enzyme activity, and U1 is the enzyme activity after incubation. If the result is a positive number, it means that the enzyme activity has decreased, and the larger the value, the worse the thermal stability of the enzyme; if the result is a negative number, it means that the enzyme activity has increased.
[0069] For example: If the initial enzyme activity of CpADH_1 is 1.200U / mg and the enzyme activity after incubation is 0.900U / mg, then It means that after CpADH_1 was incubated at 30℃ for 12h, the enzyme activity decreased by 25%.
[0070] From the results in Table 4, it can be seen that there are 7 mutants with better enzyme thermal stability than the wild type, namely CpADH_3, CpADH_4, CpADH_7, CpADH_8, CpADH_9, CpADH_11 and CpADH_12. Among them, the enzyme activity of CpADH_4, CpADH_9, CpADH_11 and CpADH_12 decreased by less than 10%, and the enzyme activity of CpADH_12 decreased the least. The enzyme thermal stability was significantly better than that of the wild type CpADH. After incubation at 30℃ for 12h, the wild type lost 30% of its activity, while CpADH_12 only lost 5% of its activity after incubation at 30℃ for 12h, retaining 95% of its activity.
[0071] Table 4 Enzyme thermal stability results of CpADH mutants
[0072]
[0073] Preparation Example 1
[0074] 50 g of ethyl condensate, 75 g of glucose, 15 mL of Triton X-100 and 7.5 mL of Tween 60 were added to a 500 mL three-necked flask, and the volume was supplemented to 1000 mL with 0.1 M PBS (pH 7.0). Subsequently, 6 M sodium hydroxide was added using a pH automatic control system to control the pH to 7.0. The mixture was placed in a 30°C water bath and stirred for 30 min. Then, 500 mg of glucose dehydrogenase, 500 mg of nicotinamide adenine dinucleotide phosphate (FMII-GD) and 100 mg of carbonyl reductase (obtained by expressing CpADH_12 in Escherichia coli BL21 (DE3)) were added. After 20 h of reaction, the conversion rate was 98.9% as determined by HPLC. Add 25 g of diatomaceous earth to the reaction system, control the temperature in a water bath to 70°C, stir and concentrate, then cool to 30°C, filter, collect the filter cake, add 1 L of water, stir and precipitate for 1 h, filter, collect the material, place in a 60°C oven to dry, dry to constant weight, and obtain ethyl hydroxylate with a purity of 99.1% and a yield of 98.6%.
[0075] Preparation Example 2
[0076] 50 g of ethyl condensate, 60 g of glucose, 20 mL of Triton X-100 and 10 mL of Tween 60 were added to a 500 mL three-necked flask, and the volume was supplemented to 1000 mL with 0.1 M PBS (pH 7.0). Subsequently, 6 M sodium hydroxide was added using a pH automatic control system to control the pH to 7.0. The mixture was placed in a 25°C water bath and stirred for 30 min. Then, 500 mg of glucose dehydrogenase, 500 mg of nicotinamide adenine dinucleotide phosphate (FMII-GD) and 100 mg of carbonyl reductase (obtained by expressing CpADH_12 in Escherichia coli BL21 (DE3)) were added. After 22 h of reaction, the conversion rate was 98.7% as determined by HPLC. Add 25 g of diatomaceous earth to the reaction system, control the temperature in a water bath to 70°C, stir and concentrate, then cool to 30°C, filter, collect the filter cake, add 1 L of water, stir and precipitate for 1 h, filter, collect the material, place in a 60°C oven to dry, dry to constant weight, and obtain ethyl hydroxylate with a purity of 99.0% and a yield of 98.4%.
[0077] Preparation Example 3
[0078] In a 500-mL three-necked flask, 60 g of ethyl condensate, 85 g of glucose, 15 mL of Triton X-100 and 7.5 mL of Tween 60 were added, and the volume was made up to 1000 mL with 0.1 M PBS (pH 7.0). Subsequently, 6 M sodium hydroxide was added using a pH automatic control system to control the pH to 7.0. The mixture was placed in a 30°C water bath and stirred for 30 min. Then, 600 mg of glucose dehydrogenase, 600 mg of nicotinamide adenine dinucleotide phosphate (FMII-GD) and 120 mg of carbonyl reductase (obtained by expressing CpADH_12 in Escherichia coli BL21 (DE3)) were added. After 20 h of reaction, the conversion rate was 98.8% as determined by HPLC. Add 25 g of diatomaceous earth to the reaction system, control the temperature in a water bath to 70°C, stir and concentrate, then cool to 30°C, filter, collect the filter cake, add 1 L of water, stir and precipitate for 1 h, filter, collect the material, place in a 60°C oven to dry, dry to constant weight, and obtain ethyl hydroxylate with a purity of 99.1% and a yield of 98.5%.
[0079] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A carbonyl reductase mutant having an amino acid sequence as shown in SEQ ID NO: 6, 11, 13 or 14.
2. A gene encoding the carbonyl reductase mutant according to claim 1.
3. An expression vector, characterized in that Containing the gene according to claim 2.
4. A strain characterized by: Contains the expression vector according to claim 3.
5. The strain according to claim 4, characterized in that The strain is Escherichia coli.
6. A method for producing a carbonyl reductase mutant, characterized in that: The steps include: The strain according to claim 4 is cultured and the culture is collected to obtain a carbonyl reductase mutant.
7. Use of the carbonyl reductase mutant according to claim 1 in catalyzing carbonyl reduction reactions.
8. The use according to claim 7, characterized in that: The catalytic carbonyl reduction reaction uses the ethyl condensate as a substrate, and performs a reduction reaction to prepare an ethyl hydroxylated levonorgestrel intermediate.
9. A method for preparing a levonorgestrel intermediate, characterized in that: The steps include: Ethyl condensate, glucose, glucose dehydrogenase, reducing coenzyme, cosolvent and the carbonyl reductase mutant according to claim 1 or the carbonyl reductase mutant obtained by the production method according to claim 6 are added to a buffer solution to obtain an ethyl hydroxylated levonorgestrel intermediate through reaction.
10. The preparation method according to claim 9, characterized in that: The concentration of the ethyl condensate is 10-100 g / L; And / or, the mass ratio of the carbonyl reductase to the ethyl condensate is 1:(100-1000); and / or, the mass ratio of the glucose to the ethyl condensate is 1:(1-2); And / or, the mass ratio of the glucose dehydrogenase to the ethyl condensate is 1:(10-1000); And / or, the mass ratio of the reducing coenzyme to the ethyl condensate is 1:(10-1000); And / or, the buffer solution is a PBS buffer solution with a pH value of 6.0-8.0; And / or, the reaction temperature is 20-40°C and the pH is 6.0-8.0; And / or, the co-solvent includes one or more of DMSO, Tween 60, Tween 80 and Triton X-100; the ratio of the volume of the co-solvent to the total volume of the reaction system is 1:(10-100).
